TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00966433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Description: The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure support Ventilation
Description: The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure control ventilation
Description: The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
Study: NCT02305979

Intervention type: DRUG
Intervention: Loratadine
Study: NCT02204189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TongFuSan
Description: TongFuSan 1g
Study: NCT04817878

Intervention type: COMBINATION_PRODUCT
Intervention: Developmental assessment
Description: Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.

Intervention type: COMBINATION_PRODUCT
Intervention: Developmental assessment
Description: Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.

Intervention type: COMBINATION_PRODUCT
Intervention: Developmental assessment
Description: Physical development assessment (head circumference, length, weight), Neurodevelopment assessment at 36 to 40 weeks of correction (GMS assessment, NBNA assessment), neurodevelopment assessment at 18 months, 24 months, and 36 months (ASQ scale, Language assessment, Wei-style scale), audiovisual screening, etc.
Study: NCT00300729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Study: NCT04228939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record aftercare
Description: Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 4-8, every other week in weeks 8-12 and once in week 16.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2.
Study: NCT02490579

Intervention type: BEHAVIORAL
Intervention: Responses to Brief Video Messages (Facebook)
Description: Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.

Intervention type: BEHAVIORAL
Intervention: Response to Brief Video Messages (Clinic)
Description: Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.

Intervention type: BEHAVIORAL
Intervention: Response to Brief Video Messages (Social Network)
Description: Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
Study: NCT00522665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 125 mg/m2 IV days 1 and 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 125 mg/m2 IV days 1 and 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 250mg/m2 IV days 1, 8 and 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 250mg/m2 IV days 1, 8 and 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RAD001
Description: Patients on Arm A will crossover and receive RAD001 at disease progression
Study: NCT00701363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Description: 120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
Study: NCT04312334

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
Study: NCT00166712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
Study: NCT01803412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisapersen
Description: Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
Study: NCT01094210

Intervention type: DRUG
Intervention: Fluorides, Topical
Description: 500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.

Intervention type: DRUG
Intervention: Fluorides, Topical
Description: 500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
Study: NCT02173847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty
Description: Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to cut a particular shaped graft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser
Description: Low power, near infrared diode laser for welding the surgical wound
Study: NCT03082404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
Study: NCT02516332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Aerobic Exercise
Study: NCT02482168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody
Study: NCT02743455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA-720
Description: The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA-720
Description: The vaccine adjuvant ISA 720 will be used with Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) as vaccine adjuvant with a depot effect. This comprises slow release of antigen at the injection site, protection of antigen against degradation and strong stimulation of the immune response.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA Smallpox Vaccine
Description: Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine (MVA BN(R)) is a purified live vaccine will be used as an active comparator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN Yellow Fever Vaccine
Description: Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.
Study: NCT03029221

Intervention type: OTHER
Intervention: PREP 8.0 curriculum developed by PREP
Description: healthy marriage and relationship education

Intervention type: OTHER
Intervention: Within My Reach curriculum developed by PREP
Description: healthy marriage and relationship education

Intervention type: OTHER
Intervention: Within Our Reach 8 Hours curriculum
Description: healthy marriage and relationship education

Intervention type: OTHER
Intervention: Within Our Reach 8 Hours curriculum
Description: healthy marriage and relationship education
Study: NCT00693667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH3
Description: Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
Study: NCT02851888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Sham Injection
Description: Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General Anesthesia
Description: Patients were induced and maintained in a fashion consistent with standard practices.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: Patients were induced and maintained in a fashion consistent with standard practices.
Study: NCT02743455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN Yellow Fever Vaccine
Description: Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN Yellow Fever Vaccine
Description: Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN Yellow Fever Vaccine
Description: Modified Vaccinia Ankara-Bavarian Nordic-Yellow Fever (MVA-BN-YF) clinical trial material is manufactured in CEF cells derived from Specific Pathogen Free (SPF) eggs in a bioreactor culture using serum free medium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: YF Vax 17D Strain
Description: Yellow Fever Vaccine (YF-VAX) is a vaccine prepared by culturing the 17D-204 strain of yellow fever virus in living avian leucosis virus-free (ALV-free) chicken embryos. Will be used as an active comparator.
Study: NCT02635607

Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin Beta
Description: Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.

Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin Beta
Description: Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.

Intervention type: DRUG
Group type: OTHER
Intervention: Ganirelix
Description: Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation

Intervention type: DRUG
Group type: OTHER
Intervention: Ganirelix
Description: Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels\>600 pg/ml; and (iii) serum LH levels\>10 IU/l.

Intervention type: DRUG
Group type: OTHER
Intervention: rhCG
Description: An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed

Intervention type: DRUG
Group type: OTHER
Intervention: rhCG
Description: An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed

Intervention type: DRUG
Group type: OTHER
Intervention: triptorelin
Description: 0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation

Intervention type: DRUG
Group type: OTHER
Intervention: triptorelin
Description: 0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
Study: NCT02763644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316 active drug
Description: LFG316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316 active drug
Description: LFG316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: SoC (site specific)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: SoC (site specific)
Study: NCT02030522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Description: The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on.